Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-29
2011-03-29
Desai, Rita J (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C548S517000, C544S144000, C544S146000, C544S224000, C514S326000, C514S218000, C514S231500
Reexamination Certificate
active
07915420
ABSTRACT:
The invention provides novel GlyT2 inhibiting compounds useful in modulating, treating, or preventing: anxiolytic disorders; a condition requiring treatment of injured mammalian nerve tissue; a condition amenable to treatment through administration of a neurotrophic factor; a neurological disorder; or obesity; an obesity-related disorder.
REFERENCES:
patent: 1069113 (2001-01-01), None
patent: WO 01/85694 (2001-11-01), None
Caulfield, W.L. et al., “The first potent and selective inhibitors of the glycine transporter type 2”, Journal of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 44, No. 17, Aug. 2001, pp. 2679-2683.
Combs, A.P. et al., “Protein Structure-Based Combinatorial Chemistry: Discovery of Non-Peptide Binding Elements to SRC SH3 Domain”, Journal of the American Chemical Society, American Chemical Society, Washington DC, US, vol. 118, 1996, pp. 287-288.
Evans, J. et al. Cloning, Functional Characterization and Population Analysis of a Variant Form of the Human Glycine Type 2 Transporter. FEBS Lett. 1999, 463(3):301-306.
Friauf, E. et al. Developmental Expression of the Glycine Transporter GLYT2 in the Auditory System of Rats Suggests Involvement in Synapse Maturation. J. Comp. Neurol. 1999, 412(1):17-37.
Gallagher, M.J. et al. Characterization of Multiple Forms of the Human Glycine Transporter Type-2. Mol. Brain Res. 1999, 70(1):101-115.
Geerlings, A. et al. Characterization of the Interactions Between the Glycine Transporters GLYT1 and GLYT2 and the SNARE protein syntaxin 1A. FEBS Letters 2000, 470:51-54.
Grenningloh, G. et al. The Strychnine-binding Subunit of the Glycine Receptor Shows Homology with Nicotinic Acetylcholine Receptors. Nature (London) 1987, 328(16):215-220.
Guastella, J. et al. Cloning, Expression, and Localization of a Rat Brain High-Affinity Glycine Transporter. Proc. Natl. Acad. Sci. U.S.A. 1992, 89(15):7189-7193.
Huang, W. and R.K. Simpson. Long-term Intrathecal Administration of Glycine Prevents Mechanical Hyperalgesia in a Rat Model of Neuropathic Pain. Neurol. Res. 2000, 22:160-164.
Isaac et al., “5, 5-Diaryl-2-amino-4-pentenoates as novel, potent, and selective glycine transporter type-2 reuptake inhibitors”, Bioorganic & Medicinal Chemistry Letters, Oxford, GB, vol. 11, 2001, pp. 1371-1373.
Isaac, M. Synthesis and Structure Activity Relationship of Novel Chiral Ligans for the Glycine-Reuptake Transporter Type-2 (GlyT-2). Abstracts of Papers, 228th ACS National Meeting, Philadelphia, PA, U.S., Aug. 22-26, 2004.
Iversen, L.L. Role of Transmitter Uptake Mechanism in Synaptic Neurotransmission. Br. J. Pharmacol. 1971, 41(4):571-591.
Krnjevic, K. Chemical Nature of Synaptic Transmission in Vertebrates. Physiol. Rev. 1974, 54(2):418-540.
Liu, Q-R. et al. Cloning and Expression of a Spinal Cord- and Brian-Specific Glycine Transporter with Novel Structural Features. J. Biol. Chem. 1993, 268(30):22802-22808.
Lopez-Corcuera, B. et al. Differential Properties of Two Stably Expressed Brain-Specific Glycine Transporters. J. Neurochem. 1998, 71(5):2211-2219.
Luque, J.M. et al. Cellular Expression of Glycine Transporter 2 Messenger RNA Exclusively in Rat Hindbrain and Spinal Cord. Neuroscience 1995, 64(2):525-535.
Ponce, J. et al. Transmembrane Domaine III Plays an Important Role in Ion Binging and Permeation in the Glycine Tranporter GLYT2. J. Biol. Chem. 2000, 275(18):13856-13862.
Probst, A. et al. The Distribution of Glycine Receptors in the Human Brain. A Light Microscopic Autoradiographic Study Using [3H]Strychnine. Neuroscience 1986, 17(1):11-35.
Raiteri, L. et al. Glycine Taken Up Through GLYT1 and GLYT2 Heterotransporters into Glutamatergic Axon Terminals of Mouse Spinal Cord Elicits Release of Glutamate by Homo-Transporter Reversal and Through Anion Channels. Biochem. Pharm. 2005, 69(1):159-168.
Rajendra, S. and P.R. Schofield. Molecular Mechanisms of Inherited Startle Syndromes. Trends Neurosci. 1995, 18(2):80-82.
Simpson, R.K., Jr. et al. Reduction in the Mechanonociceptive Response by Intrathecal Administration of Glycine and Related Compounds. Neurochem. Res. 1996, 21(10):1221-1226.
Wolin, R.L. et al., “Inhibitors of the glycine transporter type-2 (GlyT-2): syntehsis and biological activity of benzoylpiperidine derivatives”, Bioorganic and Medicinal Chemistry, vol. 12, 2004, pp. 4511-4532.
Wolin, R.L. Novel Glycine Transporter Type-2 Reuptake Inhibitors. Part 1: a-Amino Acid Derivatives. Bioorg. Med. Chem. 2004, 12(16):4477-4492.
Young, A.B. and S.H. Snyder. Strychnine Binding Associated with Glycine Receptors of the Central Nervous System. Proc. Natl. Acad. Sci. U.S.A. 1973, 70(10):2832-2836.
Zarbin, M.A. et al. Glycine Receptor: Light Microscopic Autoradiographic Localization with [3H]Strychnine. J. Neurosci. 1981, 1(5):532-547.
Huang Charles Q.
Lovenberg Timothy W.
Santillán, Jr. Alejandro
Tang Liu Y.
Wolin Ronald L.
Desai Rita J
Harbour John
Janssen Pharmaceutica NV
LandOfFree
Aryl piperidine amides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aryl piperidine amides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl piperidine amides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2757903